Braftovi
NDC Package 70255-020-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Braftovi is encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). Marketed by Array Biopharma Inc., this product is identified by NDC 70255-020 and is authorized under FDA application NDA210496.

Identification & Billing

NDC Package Code
70255-020-01
Package Description
2 BOTTLE in 1 CARTON / 60 CAPSULE in 1 BOTTLE (70255-020-02)
Product Code
70255-020
11-Digit Billing Format
70255002001
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
2 EA

Clinical Specifications

Proprietary Name
Braftovi
Dosage Form
-
Usage Information
Encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Array Biopharma Inc.
FDA Application #
NDA210496
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-27-2018
End Marketing Date
04-17-2020
Listing Expiration
04-17-2020
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70255-020-01 identifies a specific commercial package of 2 bottle in 1 carton / 60 capsule in 1 bottle (70255-020-02) of Braftovi, labeled by Array Biopharma Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 2 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Array Biopharma Inc. on June 27, 2018. The current certification is valid through April 17, 2020.

What are the primary indications for this medication?

Encorafenib is used to treat certain types of cancer (such as melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

How is this Array Biopharma Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70255002001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70255-020-01
11-Digit CMS (5-4-2)
70255-0020-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.